文献速递慢阻肺

西班牙COPD患者单吸入器与多吸入器三联疗法的临床特征、治疗持续性与结局:回顾性分析

Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
PubMed 文献 · Chest · 2022-07-03

该回顾性队列研究基于西班牙BIG-PAC数据库,纳入2018年6月至2019年12月启动单吸入器三联疗法(SITT)或多吸入器三联疗法(MITT)的COPD患者共4625例。12个月随访显示,SITT组治疗持续性更高(HR=1.37),急性加重风险更低(HR=0.68),全因死亡风险更低(HR=0.67),且医疗资源使用更少(年均节省403欧元)。

要点

  • SITT较MITT显著提高治疗持续性(HR=1.37)
  • SITT降低急性加重风险(HR=0.68)和全因死亡风险(HR=0.67)
  • SITT年均医疗费用较MITT节省403欧元

核心结论

  • 启动SITT的COPD患者治疗持续性临床相关改善,进而降低死亡、急性加重发生率及医疗资源使用并节省平均费用。

研究设计与样本

  • 真实世界、观察性、回顾性队列研究,分析西班牙国家医疗系统BIG-PAC数据库电子健康记录。
  • 纳入2018年6月1日至2019年12月31日启动SITT或MITT(使用两或三种吸入器)的年龄≥40岁COPD患者,随访12个月。
  • 共纳入4625例患者,其中SITT组1011例,MITT组3614例。

主要发现

  • 12个月随访时,SITT组较MITT组治疗持续性更高(HR=1.37;95%CI=1.22-1.53;P<.001)。
  • SITT组较MITT组急性加重风险降低(HR=0.68;95%CI=0.61-0.77;P=.001)。
  • SITT组较MITT组全因死亡风险降低(HR=0.67;95%CI=0.63-0.71;P=.027)。
  • SITT与医疗资源使用显著减少相关,年均费用较MITT节省403欧元。
  • SITT和MITT两组中,持续治疗者较非持续治疗者急性加重率改善,调整后年均费用分别节省2115欧元和2700欧元。

临床怎么用

  • 在COPD患者中启动三联疗法时,优先考虑单吸入器方案可能提高治疗持续性并改善急性加重和死亡结局。
  • 提高治疗持续性可能带来急性加重率改善和医疗费用节省。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COPD is a leading cause of death and disability. COPD therapy goals include reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT) is indicated for patients with frequent exacerbations despite bronchodilator therapy. No available evidence compares SITT vs MITT in Spain in terms of treatment persistence, exacerbations, and other outcomes. RESEARCH QUESTION: Do COPD patients in Spain initiating SITT vs MITT have improved persistence, exacerbations, and health care resource utilization? STUDY DESIGN AND METHODS: This real-world, observational, retrospective cohort study analyzed electronic health records in the Spanish National Healthcare System BIG-PAC database to identify COPD patients aged ≥ 40 years initiating SITT or MITT (using two or three inhalers) between June 1, 2018 and December 31, 2019. Comparative data on persistence (allowing up to 60 days without prescription refill), exacerbation rates, and health care resource utilization and costs during 12-month follow-up were analyzed. Multivariate adjusted analyses were performed. RESULTS: Eligible patients (N = 4,625) initiating SITT (n = 1,011) or MITT (n = 3,614) had a mean age of 70.9 years; most were male (73.9%) with mainly moderate (62.0%) or severe (26.5%) airflow limitation. Between-cohort baseline characteristics were similar. At 12-month follow-up, SITT patients had higher persistence (hazard ratio [HR] = 1.37; 95% CI = 1.22-1.53; P < .001), reduced risk of exacerbations (HR = 0.68; 95% CI = 0.61-0.77; P = .001), and lower all-cause mortality risk (HR = 0.67; 95% CI = 0.63-0.71, P = .027), compared with MITT patients. SITT was associated with significantly reduced health care resource use (mean annual cost savings: €403 vs MITT). For both SITT and MITT, persistence was associated with improved exacerbation rates vs nonpersistence, and substantial adjusted mean annual cost savings (€2,115 and €2,700, respectively). INTERPRETATION: Patients initiating SITT had a clinically relevant improvement in persistence leading to reductions in mortality, incidence of exacerbations, and health care resource use with consequent mean cost savings.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Alcázar-Navarrete, Jamart, Sánchez-Covisa, et al. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. Chest. 2022. PMID: 35787391. doi:10.1016/j.chest.2022.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。